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                                     Aim of the study  
 
1. To estimate various level of lipids in CRF patients. 
2. To study whether any correlation exist between the severity of CRF 
and lipid alterations. 
3. To examine which type of hyperlipoproteinemia predominates in 
these patients. 
4. To examine whether the ratio between TC to HDL-C is altered in CRF 
patients. 
5. To examine the association of hypertension in CRF patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
 
       The national kidney foundation criteria for diagnosis of CKD are : 
(i) Kidney damage for greater than or equal to 3 months, as defined by 
structural or functional abnormalities of the kidney, with or without 
decreased glomerular filtration rate, manifest by either: 
a. pathological abnormalities or 
b. markers of kidney damage, including abnormalities in the               
composition of the blood or urine, or abnormalities in imaging 
tests. 
(ii) Glomerular filtration rate less than 60 mL/min/1.73 m2 for greater than 
or equal to 3 months, with or without kidney damage Ref. 1 .  
 
        In accordance with the Kidney Disease Outcomes Quality Initiative 
(KDOQI) definition, a documented GRF of below 60mL/min/1.73 m2 fulfils 
the definition of CKD without requiring any additional evidence of 
underlying kidney damage. This cutoff in GFR was selected because it 
represents over 50% reduction in kidney function as compared to the level 
for young healthy adults and it is supported by accumulating evidence 
demonstrating the presence of  complications as  the  glomerular filtration  
rate falls below  60 mL/min/1.73 m2.   
 
      The commonest and most readily available marker of kidney damage 
resulting in glomerular dysfunction is the presence of proteinuria. Similarly, 
the presence of abnormal sediment on urine microscopy or the 
demonstration of multiple cysts on renal imaging in a patient with a family 
history of polycystic kidney disease would meet the requirement for 
objective kidney damage. Because the relationship of hypertension to kidney 
disease is complex and varied, hypertension by itself is not included in the 
above definition; instead the presence of absence of hypertension is noted 
separately in conjunction with the presence or absence and the severity of 
CKD. 
 
      Stage I represents subjects who do not have a clear filtration deficit and 
is defined as a normal or elevated kidney function (GRF>90ml/min/1.73m2) 
in association with evidence of kidney damage , this latter is defined broadly 
but is most often represented by the presence of persistent albuminuria. 
Stage II is a mild reduction in kidney function (GRF 60-89 ml/min/1.73m2) 
that occurs in association with kidney damage. CKD stages III and IV    
correspond to moderately and severely decreased kidney function (GRF of 
30-59 and 15-29 ml/min/1.73 m2 respectively). This large a decrement in 
kidney function is classified as CKD regardless of the presence of additional 
evidence of kidney damage. Stage V represents kidney failure defined by 
either a GRF below 15 or the need for renal replacement therapy. 
 
       The most important parameter in the clinical evaluation of kidney 
function is the glomerular filtration rate (GFR), which is generally accepted 
as the best over all index of kidney function. The level of GRF correlates 
well (albeit not perfectly) with the likelihood of developing complications of 
kidney disease, such as anemia, hyperphosphatemia and uremic symptoms.   
 
       Since its introduction by Homer Smith, the gold standard for 
measurement of GRF has been clearance of the small carbohydrate moiety 
inulin (an 5200d uncharged polymer of fructose)-an ideal filtration marker 
because it is freely filtered in the glomeruli and is neither reabsorbed nor 
secreted by the tubules. Because clearance is defined as the volume of 
plasma cleared entirely of a substance in a unit of time, clearance of inulin 
equals GRF. Direct measure of GRF using inulin clearance is cumbersome, 
requiring intravenous infusion and timed urine collection. In research 
studies, GRF has been measured by clearance of iothalamate (a small 
polyiodinated radiographic contrast molecule that can be radiolabeled), but 
that is also not clinically practical.   
 
       In daily clinical practice, serum creatinine concentration (SCr) has been 
the most commonly used parameter to evaluate kidney function. The small 
molecule creatinine (molecular weight 113 daltons) is endogeneously 
produced by muscle and excreted by the kidneys. Therefore, the reduction in 
GRF leads to an increase in SCr. Serum creatinine is easily and cheap to 
measure, and no urine collection is needed. Many laboratories report a 
normal reference range for SCr of around 0.7 to 1.4 mg/dL. 
 
       However, the national kidney foundation CKD guidelines explicitly 
recommend that clinicians “should not use serum creatinine as the sole 
means to assess the level of kidney function”. This departure from current 
clinical practice needs an explanation. One known problem is that renal 
creatinine clearance tends to over estimate GRF. More importantly, serum 
creatinine often does not reflect underlying GRF because SCr is a function 
not only of creatinine clearance (which reflects kidney function) but also 
creatinine production (which largely reflects muscle mass). Therefore, the 
same SCr can represent very different underlying glomerular filtration rates 
in individuals because of muscle mass difference.  
 
       A clinically practical solution to this problem is to use SCr to estimate 
kidney function via equations that take into account variables such as age, 
sex, race, and body size (which are all important predictors of muscle mass 
and hence creatinine production).      
       A commonly used surrogate marker for actual creatinine clearance is the 
Cockcroft-Gault formula, which may be used to calculate an Estimated 
Creatinine Clearance, which in turn estimates GFR: It is named after the 
scientists who first published the formula, and it employs creatinine 
measurements and a patient's weight to predict the Creatinine clearance. The 
formula, as originally published, is: 
 
For creatinine in µmol/L: 
 
Where Constant is 1.23 for men and 1.04 for women.  
Estimated GFR (eGFR) using Modification of Diet in Renal Disease 
(MDRD) formula 
       The most recently advocated formula for calculating the GFR is the one 
that was developed by the Modification of Diet in Renal Disease Study 
Group. The most commonly used formula is the "4-variable MDRD" which 
estimates GFR using four variables: serum creatinine, age, race, and gender. 
The original MDRD used six variables with the additional variables being 
the blood urea nitrogen and albumin levels. The equations have been 
validated in patients with chronic kidney disease; however both versions 
underestimate the GFR in healthy patients with GFRs over 60 mL/min. The 
equations have not been validated in acute renal failure. 
For creatinine in mg/dL: 
 
 
        When  SCr is changing rapidly, such as during acute renal failure, it is 
wrong to estimate GRF using the Cockcroft-Gault or the MDRD equation. It 
may be possible under those circumstances to model the underlying kidney 
functions from the rate and pattern of change in SCr using complex 
mathematical models beyond the scope of usual clinical practice. 
        For patients with unusual body compositions or extremes of body sizes, 
SCr based equations will likely give invalid estimates of GRF because of 
alterations in the usual relationship between muscle mass and parameters 
such as age, sex, and weight. Examples include patients with hepatic 
cirrhosis, limb amputation, spinal cord injury or morbid obesity. For these 
patients, multiple 24-hr urine collections (to reduce inaccuracies in 
collection) may be the best way to evaluate GRF.  
       As GFR declines, the relative proportion of creatinine secretion versus 
filtration rises. Consequently, creatinine secretion has a greater effect on the 
serum creatinine concentration at lower levels of GFR. Polycystic kidney 
disease and tubulointerstitial disease seem to be associated with lower mean 
levels of creatinine secretion than other diseases Ref 2. Higher protein intake 
can cause increased creatinine secretion. Several medications, such as 
cimetidine, trimethoprim, and fenofibrate, can inhibit tubular secretion of 
creatinine. Some have advocated administration of cimetidine to block 
creatinine secretion during 24-hour urine collections for creatinine clearance, 
thereby allowing for a more accurate measurement of GFR, especially in 
patients with moderate to severe reductions in GFR. 
 
       Creatinine generation is directly proportional to muscle mass, which in 
turn varies according to age, sex, and race and is affected by conditions 
causing muscle wasting. Creatinine generation is also affected by dietary 
meat intake, because meat includes creatine, which can be converted to 
creatinine by cooking Ref 3,4 . Increased meat intake can cause a long-term 
increase in serum creatinine because of an increase in the creatinine pool. 
 
       Extrarenal elimination of creatinine can occur in the gastrointestinal 
tract by bacterial degradation of creatinine contained in intestinal secretions. 
Extrarenal elimination is not detectable in normal individuals, but may 
account for up to 68% of daily creatinine generation in patients with 
severely reduced GFRRef 5,6 because of increased concentration of creatinine 
in gastrointestinal secretions and bacterial overgrowth of the upper 
gastrointestinal tract. 
 
        In principle, antibiotics could cause an increase in serum creatinine in 
patients with CKD because of eradication of bacterial overgrowth and 
decrease in extrarenal elimination of creatinine. This may be a relevant 
consideration in patients with CKD who develop superimposed acute renal 
failure. 
  
 Factors affecting glomerular filtration rate 
• Kidney disease 
• Pregnancy 
• Reduced kidney perfusion 
• Marked increase or deficit of extracellular fluid volume 
• Nonsteroidal anti-inflammatory drug use 
• Acute protein load and habitual protein intake 
• Blood glucose control (in patients with diabetes) 
• Level of arterial blood pressure and class of antihypertensive 
• Agents used. 
                                                                                                                         
Clinical applications 
       Accurate estimation of GFR is critical to care of patients with CKD. The 
current staging system for CKD is built primarily on the level of GFR in that 
as GFR declines, the stage increases. Decreasing levels of GFR (or higher 
CKD stage) are associated with a higher prevalence of a wide range of 
symptoms and complications including hypertension, anemia, malnutrition, 
bone disease, and neuropathy. At each stage, accurate assessment of GFR is 
required for evaluation and treatment. Currently, the most accurate method 
for estimation of GFR seems to be the MDRD Study equation.  
 
       Estimation of GFR from the MDRD Study equation is not appropriate 
for all patients. In these patients, a clearance measurement (either a 24-hour 
urine collection for creatinine clearance or an exogenous filtration) can be 
used. 
 
A 24-hour urine collection may be required to estimate glomerular 
filtration rate in the following conditions 
• Extremes of age and body size 
• Severe malnutrition or obesity 
• Disease of skeletal muscle 
• Paraplegia or quadriplegia 
• Vegetarian diet 
• Rapidly changing kidney function 
• Pregnancy 
• Before dosing drugs with significant toxicity that are excreted by the 
kidneys 
        The uremic syndrome and the disease state associated with advanced 
renal impairment involve more than renal excretory failure. A host of 
metabolic and endocrine functions normally undertaken by the kidneys are 
also impaired, and this results in anemia, malnutrition, and abnormal 
metabolism of carbohydrates, fats, and proteins. Furthermore, plasma levels 
of many hormones, including PTH, insulin, glucagon, sex hormones, and 
prolactin, change with renal failure as a result of urinary retention, decreased 
degradation, or abnormal regulation. Finally, progressive renal impairment is 
associated with worsening systemic inflammation. Elevated levels of C-
reactive protein are detected along with other acute-phase reactants, while 
levels of so-called negative acute-phase reactants, such as albumin and 
ferritin, decline with progressive renal impairment. Thus, renal impairment 
is important in the malnutrition-inflammation-atherosclerosis/calcification 
syndrome, which contributes in turn to the acceleration of vascular disease 
and comorbidity associated with advanced renal disease. 
Major Causes of Chronic Kidney Disease 
       Causes are Chronic tubulointerstitial nephropathies; Primary 
Glomerulopathies (Focal glomerulosclerosis, Idiopathic crescentic 
glomerulonephritis, IgA nephropathy, membranoproliferative 
glomerulonephritis ,Membranous nephropathy); Glomerulopathies 
associated with systemic disease (Amyloidosis, Diabetes mellitus, 
Hemolytic-uremic syndrome, Postinfectious glomerulonephritis, SLE 
Wegener's granulomatosis); Hereditary nephropathies (Hereditary nephritis - 
Alport's syndrome, Medullary cystic disease, Nail-patella syndrome, 
Polycystic kidney disease); Hypertension (Malignant glomerulosclerosis, 
Nephroangiosclerosis); Obstructive uropathy (Benign prostatic hyperplasia 
,Posterior urethral valves Retroperitoneal fibrosis, Ureteral obstruction by 
congenital, calculi, malignancies and Vesicoureteral reflux);  Renal 
macrovascular disease (vasculopathy of renal arteries and veins) ; Renal 
artery stenosis caused by atherosclerosis or fibromuscular dysplasia. 
 
       The incidence of cardiovascular disease (CVD) is substantially higher in 
patients with chronic kidney disease (CKD) compared with the general 
population Ref 7. Studies have shown that hemodialysis patients with high 
cholesterol have lower mortality than those with low cholesterol. 
Dyslipidemias have also been linked to the rate of decline in kidney 
function, and it is possible that treatment of dyslipidemias may slow the rate 
of CKD progression Ref 8.  The dyslipidemias associated with early stages of 
CKD generally worsen with advancing kidney failure and ultimately affect 
most patients treated with maintenance dialysis and kidney 
transplantation.Ref 9,10. 
 
 
 
Frederickson Classification of Dyslipidemia 
                                                                                                                                                      
 
Hyperlipoproteinemia   Problems   Labs description   Treatment   
Type I 
Decreased lipoprotein 
lipase (LPL) or 
altered ApoC2 
Elevated 
Chylomicrons 
Diet Control 
Type IIa LDL receptor deficiency Elevated LDL only 
Bile Acid 
Sequestrants, 
Statins, Niacin 
Type IIb 
Decreased LDL 
receptor and 
Increased ApoB 
Elevated LDL and 
VLDL and 
Triglycerides 
Statins, Niacin, 
Fibrate 
Type III 
Defect in ApoE 
synthesis 
Increased IDL 
Drug of choice: 
Fibrate 
Type IV 
Increased VLDL 
production and 
Decreased elimination
Increased VLDL 
Drug of choice: 
Fibrate, Niacin 
Type V 
Increased VLDL 
production and 
Decreased LPL 
Increased VLDL 
and Chylomicrons 
 
        CRF results in profound dysregulation of several key enzymes and 
receptors involved in the metabolism of lipoproteins, particularly those of 
HDL and triglyceride-rich lipoproteins. Downregulation of LCAT, apoA-1, 
and hepatic lipase together with upregulation of CETP are largely 
responsible for the reduction in HDL cholesterol and elevation of 
triglyceride in CRF. 
 
        Downregulation of skeletal muscle and adipose tissue LPL, hepatic 
lipase, and the VLDL receptor and of hepatic LRP is collectively responsible 
for hypertriglyceridemia, impaired clearance, and elevated plasma levels of 
VLDL, IDL, and chylomicron remnants despite downregulation of hepatic 
triglyceride synthetic capacity (DGAT). Dysregulation of lipid metabolism 
can contribute to atherogenic diathesis and possibly to progression of renal 
disease and impaired energy metabolism in CRF. 
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Review of literature 
 
       CHRONIC RENAL FAILURE (CRF) is associated with premature 
atherosclerosis and increased incidence of cardiovascular morbidity and 
mortality.Ref 11,12,13. Several factors contribute to atherogenesis and 
cardiovascular disease in patients with CRF. Notable among the CRF-
induced risk factors are lipid disorders, oxidative stress, inflammation, 
physical inactivity, anemia, hypertension, vascular calcification, endothelial 
dysfunction, and depressed nitric oxide availability Ref 14,15,16,17. 
 
       CVD as the major cause of mortality in patients with mild to moderate 
CKD and end-stage renal disease (ESRD) Ref 18,19. Approximately 50% of 
patients with ESRD die from a cardiovascular event Ref 20, which indicates a 
cardiovascular mortality that is 30 times higher in dialysis patients and 500 
times higher in 25- to 34-year-old ESRD patients than in individuals from 
the general population of the same age and race. 
 
       In a retrospective cohort study only a tiny minority of patients (0.5–1%) 
with mild to moderate CKD developed ESRD over a 5-year follow-up, while 
as many as 19 and 24% of these patients with mild and moderate renal 
insufficiency, respectively, died mostly of cardiovascular complications in 
the same period Ref 21. Dyslipidemia has been established as a well-known 
traditional risk factor for CVD in the general population and large-scale 
observational studies have shown that total and low-density lipoprotein 
(LDL)-cholesterol values are two of the most important independent 
predictors of cardiovascular morbidity and mortality Ref 22  . Also, it is well 
known that patients with impaired renal function exhibit significant 
alterations in lipoprotein metabolism, which in their most advanced form 
may result in the development of severe dyslipidemia. 
 
       In the plasma, lipids are carried by water-soluble particles known as 
lipoproteins, which consist of a nonpolar lipid core (triglycerides, cholesterol 
esters) surrounded by an envelope composed of specific apolipoproteins 
(apo), phospholipids, and other polar lipids. The plasma lipoproteins are 
commonly classified as either high-density (HDL), low-density (LDL), 
intermediate-density (IDL), or very-low-density (VLDL) lipoproteins 
according to their ultracentrifugation characteristics. Chylomicrons and 
VLDL serve as vehicles to transport triglycerides and cholesterol from the 
sites of absorption (intestine) and endogenous production (liver) to the sites 
of consumption (myocytes, steroidogenic glands, etc.) or storage 
(adipocyte). In contrast, HDL serves as a vehicle to transport surplus 
cholesterol from peripheral tissues to the liver for disposal. 
 
       The typical profile of patients with chronic kidney disease, that is, the 
constellation of moderate elevation of plasma triglyceride concentrations, 
combined with low plasma HDL-cholesterol, corresponds to the pattern of 
dyslipidemia type IV according to Frederickson et al. In CKD, total 
cholesterol is usually normal or even low. This may be the result of an 
additional microinflammatory state and/or malnutrition. 
 
       Although lipid abnormalities were originally considered as 
complications of ESRD, these changes can be present in early stages of 
CKD and may actively participate in the pathogenesis of serious 
complications such as atherosclerotic vascular disease. Although the nature 
of dyslipidemia can be significantly influenced by several intrinsic 
(nephrotic range proteinuria, concomitant diseases such as diabetes mellitus, 
hereditary disorders of lipid metabolism) or exogenous (epoietin 
administration, drugs such as steroids, calcineurin inhibitors, etc.) factors, 
the most common quantitative lipid abnormalities in predialysis CKD 
patients are hypertriglyceridemia, increased concentrations of triglyceride-
rich lipoprotein remnants, reduced high-density lipoprotein (HDL)-
cholesterol levels as well as increased concentrations of lipoprotein(a) Lp(a). 
  
       Notably, total and LDL-cholesterol levels are usually within normal 
limits or slightly reduced in these individuals Ref 23. Hypertriglyceridemia 
represents an early feature of renal failure. Indeed, previous studies have 
shown that patients with impaired renal function exhibit increased 
concentrations of triglycerides even though serum creatinine levels are 
within normal limits Ref 24,25. In addition, individuals with renal insufficiency 
usually display abnormal increases  in serum  triglyceride levels after a fat 
meal (postprandial lipemia) Ref 26. 
 
        Studies revealed that the accumulation of triglyceride-rich lipoproteins 
(very-low-density lipoprotein (VLDL), chylomicrons and their remnants) in 
individuals with predialysis CKD is mainly due to their decreased 
catabolism Ref 27. The downregulation of the expression of several genes Ref 
28,29,30, along with the changes in the composition of lipoprotein particles Ref 
31, and the direct inhibitory effect of various uremic ‘toxins’ on the enzymes 
involved in lipid metabolism Ref 32, represent the most important 
pathophysiological mechanisms underlying the development of 
hypertriglyceridemia in renal failure.         Interestingly, it has been proposed 
that secondary hyperparathyroidism may also contribute to the impaired 
catabolism of triglyceride- rich lipoproteins Ref 33,34, and that 
parathyroidectomy or the administration of the calcium channel blocker 
verapamil Ref 35,  may partially ameliorate the hypertriglyceridemia of CKD. 
 
       Nonnephrotic patients with stages 2 to 4 CKD generally have normal 
LDL levels, but triglycerides may be elevated and HDL may decrease the 
level of kidney function declines. This may be caused by reduced lipoprotein 
lipase activity. Among those are chronic exposures to high parathyroid 
hormone levels resulting in reductions in both hepatic triglycerides lipase 
and lipoprotein lipase Ref 36 .Calcium accumulation in pancreatic islet cells 
with subsequent functional impairment of pancreas and glucose intolerance 
has also been postulated Ref 37.Patient with CKD also have elevated Apo C-
111 levels that may be associated with reduced lipoprotein lipase activity. It 
is well known that impaired insulin sensitivity represents an early feature of 
CKD. Thus, it could be hypothesized that the insulin resistance- driven 
overproduction of VLDL may significantly contribute to the development of 
hypertriglyceridemia in CKD patients. 
 
       Epidemiological studies have shown that HDL-cholesterol levels are 
inversely related to the future cardiovascular risk Ref 38. HDL particles 
possess multiple antiatherogenic activities including reverse cholesterol 
transport (transport of surplus cholesterol from the arterial wall to the liver 
for excretion) as well as antioxidative, anti-inflammatory and antithrombotic 
functions, which are attributed to HDL-associated apolipoproteins (mainly 
apolipoprotein AI) and enzymes (paraoxonase-1, platelet- activating factor 
acetylhydrolase and lecithin-cholesterol acyltransferase (LCAT)) Ref  39. 
 
        Studies in patients or laboratory animals with predialysis renal failure 
consistently reveal decreased concentrations of HDL-cholesterol compared 
to individuals with normal renal function Ref 40,41. Several mechanisms, 
working in concert, may underlie this reduction in HDL-cholesterol levels, 
which is usually indicative of impaired reverse cholesterol transport. Thus, 
uremic patients usually exhibit decreased levels of apolipoproteins AI and 
AII (the main protein constituents of HDL), diminished activity of LCAT 
(the enzyme responsible for the esterification of free cholesterol in HDL 
particles) Ref 42. As well as increased activity of cholesteryl ester transfer 
protein Ref 43, that facilitates the transfer of cholesterol esters from HDL to 
triglyceride-rich lipoproteins thus reducing the serum concentrations of HDL 
cholesterol. In addition to their reduced efficiency as cholesterol acceptors, 
HDL particles from individuals with renal failure may also possess impaired 
antioxidative and anti-inflammatory function. This impairment can, at least 
in part, be attributed to the reduction in the activities of HDL-associated 
enzymes Ref 44,45. 
 
       Plasma HDL concentration is consistently reduced, and maturation of 
cholesterol ester-poor HDL-3 to cholesterol ester-rich cardioprotective 
HDL-2 is impaired in CRF Ref 46,47,48,49. The recently proposed index of non-
HDL-cholesterol, reflecting the sum of LDL and VLDL particles appears to 
be more sensitive and is a superior predictor of cardiovascular risk Ref 
50,51.Lp(a) represents an LDL-like particle distinguished from LDL by the 
presence of apolipoprotein(a) (apo(a)), which is attached to the 
apolipoprotein B-100 molecule through disulfide linkage Ref 52 . Apo(a) is 
highly homologous to the plasma protease zymogen plasminogen and thus it 
has been suggested that Lp(a) may promote thrombogenesis by inhibiting 
fibrinolysis .The large concentration gradient of Lp(a) between the aorta and 
renal vein Ref 53 as well as the identification of apo(a) fragments in urine Ref  54 
suggest that the kidney may actively participate in the degradation of Lp(a). 
Thus, it is not surprising that patients with primary kidney diseases (even 
those with normal GFR values) usually exhibit markedly elevated 
concentrations of Lp (a) Ref 55,56 as well as increased concentrations of LDL-
unbound apo(a) Ref 57 . IDL, an intermediate of VLDL catabolism, 
accumulates in the plasma of CKD patients Ref  58,59,60. The IDL concentration 
is a predictor of the severity or progression of atherosclerosis Ref 61. 
 
       Chylomicrons, that is, large triglyceride-rich particles of intestinal 
origin, are only transiently present in plasma in the postprandial state under 
physiological conditions Ref 62. It has been postulated that prolonged 
postprandial persistence of chylomicrons in the circulation causes 
endothelial damage and promotes atherosclerosis .In CKD patients, the 
clearance of chylomicrons is severely impaired Ref 63. This abnormality may 
contribute to the hypertriglyceridemia in CKD. 
 
        In addition to the aforementioned quantitative changes in serum 
lipoprotein concentrations, patients with CKD display important qualitative 
alterations in lipid metabolism that cannot be easily assessed with 
conventional laboratory techniques .Thus, it has been shown that VLDLs 
from individuals with impaired renal function have increased cholesterol 
content, while their triglyceride content is usually reduced. 
        In contrast, chronic renal failure usually results in decreased cholesterol 
content of LDLs and HDLs, whereas the triglyceride content of these 
particles is relatively increased. Finally, although uremic patients usually 
have a normal or slightly reduced LDL-cholesterol concentration, they 
exhibit important disturbances in the density distribution of LDL 
subfractions that is characterized by a predominance of small, dense LDL 
particles Ref  64,65. These particles are more atherogenic than the large, 
buoyant ones and can substantially contribute to the pathogenesis of 
atherosclerotic vascular disease Ref 66. 
 
        It should be noted that in many instances development and progression 
of renal insufficiency are accompanied by heavy proteinuria, leading to 
superimposition of nephrotic dyslipidemia Ref 67, on CRF-induced lipid 
disorders. In these circumstances, plasma total cholesterol and LDL 
cholesterol concentrations are frequently elevated. However, with 
progression to ESRD and the consequent decline in proteinuria (reduced 
filtered protein), a lipid profile typical of CRF emerges. It is of note that 
losses of proteins through the peritoneum in ESRD patients treated with 
chronic peritoneal dialysis simulate nephrotic syndrome and lead to a lipid 
profile that frequently includes hypercholesterolemia and an elevated LDL 
level. The effects of peritoneal losses of protein on lipid metabolism in 
peritoneal dialysis patients are compounded by peritoneal absorption of large 
quantities of glucose, which tends to accentuate the hypertriglyceridemia. 
 
CONSEQUENCES OF DYSLIPIDEMIA 
       Progression of Renal Disease Hyperlipidemia can potentially accelerate 
progression of renal disease by several mechanisms. First, reabsorption of 
fatty acids, phospholipids, and cholesterol contained in the filtered proteins 
(albumin and lipoproteins) by tubular epithelial cells can stimulate 
tubulointerstitial inflammation, foam cell formation, and tissue injury Ref 68,69. 
Second, accumulation of lipoproteins in glomerular mesangium can promote 
matrix production and glomerulosclerosis Ref 70,71,72. In this context, native 
and oxidized lipoproteins, particularly LDL, stimulate production of matrix 
proteins by cultured mesangial cells and promote generation of 
proinflammatory cytokines, which can lead to recruitment and activation of 
circulating and resident macrophages Ref 73,74,75. 
 
        In addition, impaired HDL-mediated reverse cholesterol transport can 
further contribute to tissue injury by limiting the unloading of the excess 
cellular cholesterol and phospholipid burden. In fact, low plasma HDL has 
been identified as an independent risk factor for progression of renal disease 
Ref 76,77.Moreover, hereditary LCAT deficiency, which is associated with a 
marked reduction in HDL cholesterol and impaired HDL-mediated reverse 
cholesterol transport, results in progressive renal disease Ref 78. The 
Modification of Diet in Renal Disease (MDRD) study identified low plasma 
HDL cholesterol as an independent risk factor for progression of renal 
disease. 
 
Cardiovascular Disease 
       The risk of cardiovascular morbidity and mortality is profoundly 
increased in patients with CKD. For instance, the majority of patients with 
CKD die of cardiovascular events before reaching ESRD. Moreover, 
cardiovascular mortality among dialysis-dependent ESRD patients is 10- to 
30- fold greater than in the general population despite stratification for 
gender, age, race, and the presence of diabetes. Numerous factors contribute 
to atherogenic diathesis and the high risk of cardiovascular disease in CKD. 
These include oxidative stress, inflammation, hypertension, and altered 
metabolism of lipids, carbohydrates, nitric oxide, calcium, and phosphate, 
among others. While plasma cholesterol concentration is frequently elevated 
in patients with nephrotic proteinuria and mild to moderate renal 
insufficiency, it is frequently normal or reduced and only occasionally 
elevated in those with ESRD. Accordingly, the high risk of cardiovascular 
disease in ESRD populations cannot be attributed to hypercholesterolemia. 
On the contrary, a reduction in plasma cholesterol (which denotes intense 
inflammation) predicts cardiovascular events Ref 79,80,81, in contrast to the 
pattern in the general population. 
 
Impact on Energy Metabolism 
       VLDL and chylomicrons are the principal vehicles for the delivery of 
fatty acids to the skeletal muscles and myocardium for energy production 
and to the adipose tissue for energy storage. Fatty acids and glucose are the 
principal sources of energy that fuel all mechanical, biochemical, and 
biophysical functions of the body. Thus impaired LPL-mediated lipolysis of 
VLDL and chylomicrons, as well as, diminished VLDL receptor-mediated 
uptake of VLDL by skeletal muscle and myocardium, can necessarily limit 
the availability of fatty acid fuel in these tissues. 
 
       An Example Of Reverse Epidemiology Following the seminal report of 
Degoulet et al. Ref 82, numerous investigators found a paradoxical inverse 
relationship between plasma cholesterol concentration and overall mortality, 
as well as cardiovascular mortality Ref 83,84. Usually a U- or J-shaped 
relationship was noted between plasma cholesterol concentration and 
cardiovascular mortality i.e., a higher mortality at low as well as high plasma 
cholesterol concentrations .The most plausible explanation for this paradox 
is that this represents an example of reverse epidemiology i.e., a relationship, 
which is reversed by a confounding factor. The recent work of Liu et al , is 
important in this respect. They identified microinflammation as a 
confounding factor. 
 
       This finding is important, because in such circumstances serum 
cholesterol and LDL cholesterol concentrations may no longer be a valid 
guide to establish the indication for lipid-lowering therapy. In the general 
population as much as 75% of the excess risk of coronary heart disease 
could be explained by traditional Framingham risk factors Ref 85. However, 
use of traditional risk factors underestimates the CVD risk in patients with 
CKD Ref 86, while the Framingham predictive instrument demonstrates poor 
overall accuracy in predicting cardiac events in patients with mild to 
moderate CKD Ref 87. Moreover, traditional CVD risk factors were found 
often to relate to outcome in ESRD dialysis patients in an opposite direction, 
a phenomenon termed ‘reverse epidemiology’.  
  
Lipids in Hemodialysis and Peritoneal Dialysis 
       Dialysis is very effective for the amelioration of uremic symptoms and 
certain features of uremic toxicity. The initiation of renal replacement 
therapy as well as the choice of dialysis modality may also influence the 
phenotypic characteristics of uremic dyslipidemia in patients with ESRD. 
However, the lipid and apolipoprotein profile that characterizes predialytic 
renal failure remains essentially unchanged during long-term hemodialysis 
(HD) Ref88. Thus, HD patients usually display increased concentrations of 
intact or partially metabolized triglyceride-rich lipoproteins, reduced serum 
levels of HDL-cholesterol and elevated concentrations of Lp (a). Total and 
LDL-cholesterol values are within normal limits or reduced in this patient 
population, whereas the subfractionation of apolipoprotein B-containing 
lipoproteins usually reveals a predominance of small, dense LDL particles. 
The pathophysiological mechanisms that underlie the alterations in 
lipoprotein metabolism in HD patients are generally similar with those 
described in predialysis renal failure individuals. 
 
       Despite the neutral effect of dialysis on serum lipid profile, certain 
dialysis-related parameters may significantly affect lipoprotein metabolism 
and modify the features of dyslipidemia in HD patients. Thus, it has been 
shown that the use of high-flux polysulfone or cellulose triacetate 
membranes instead of low-flux membranes is accompanied by a significant 
reduction in serum triglyceride levels as well as by an increase in 
apolipoprotein AI and HDL-cholesterol levels. This improvement could, at 
least in part, be attributed to an increase in the apolipoprotein C-II/C-III ratio 
which increases the activity of lipoprotein lipase and facilitates the 
intravascular lipolysis of triglyceride rich-lipoproteins. 
 
        In addition, the type of dialysate may also significantly affect the serum 
levels of lipoproteins in HD patients. Indeed, it has been shown that the use 
of bicarbonate dialysate may result in higher HDL-cholesterol 
concentrations than the use of acetate dialysate. Another factor that can 
potentially affect lipoprotein metabolism in HD patients is the repeated use 
of heparin as anticoagulant. Heparin releases lipoprotein lipase from the 
endothelial surface and thus its chronic use may result in lipoprotein lipase 
depletion and defective catabolism of triglyceride-rich lipoproteins. 
 
       Finally, recent studies indicate that the use of the phosphate-binder 
sevelamer hydrochloride significantly reduces the concentrations of total 
cholesterol and apolipoprotein B in HD patients. Obviously, the cholesterol-
lowering properties of this compound are irrelevant to phosphate reduction 
and can be mainly attributed to its bile acid sequestrating properties. 
 
       In contrast to HD patients whose serum lipoprotein concentrations 
resemble those of redialysis renal failure subjects, continuous ambulatory 
peritoneal dialysis (CAPD) patients usually exhibit a more atherogenic lipid 
profile that is characterized by higher total and LDL-cholesterol values, 
increased apolipoprotein B concentrations, and more pronounced 
hypertriglyceridemia. In addition, CAPD patients have increased 
concentrations of small, dense LDL, higher Lp (a) values and reduced HDL-
cholesterol concentrations compared to healthy age- and sex-matched 
individuals. 
 
        The pathophysiological mechanisms that exacerbate dyslipidemia in 
CAPD individuals are not well characterized. However, a number of factors 
have been proposed to play contributory roles in this exacerbation. It is well 
known that CAPD patients lose substantial amount of proteins into the 
peritoneal dialysate, resembling the protein losses observed in NS. This 
protein loss may, in turn, stimulate the hepatic production of albumin and 
cholesterol enriched lipoproteins thus leading to elevated concentrations of 
LDL-cholesterol and Lp (a). In addition, the absorption of glucose from the 
dialysis fluid and the resultant increase in insulin levels may enhance the 
hepatic synthesis and secretion of VLDL and possibly that of other 
lipoproteins such as Lp (a).  Recent studies indicate that the reduction in 
glucose load with the use of less absorbed icodextrin- containing dialysis 
solution instead of glucose for the overnight dwell sufficiently reduces the 
serum levels of total and LDL-cholesterol as well as the concentrations of 
triglycerides and small, dense LDL particles. 
 
       It should be noted that even though substantial amounts of 
apolipoproteins and intact lipoproteins (especially HDL) are lost via the 
peritoneal cavity in CAPD patients, the pathophysiological significance of 
these losses as well as their impact on lipoprotein metabolism remain 
indeterminate. In a recent study we investigated the efficiency of the 
phosphate-binder sevelamer hydrochloride in the treatment of 
hyperphosphatemia and its influence on serum lipid parameters in patients 
on CAPD. The data from this prospective, randomized, cross-over study 
indicate that, over a period of 8 weeks, the drug effectively lowered serum 
phosphorus and also had a significant beneficial effect on both total and 
LDL-cholesterol serum levels. 
 
Drug Therapy of Dyslipidemia in CKD Patients 
       Interventional studies have shown that the pharmacological reduction of 
total and LDL-cholesterol values is followed by an impressive decrease in 
the risk of the development of ischemic events. Thus, based on the 
extremely high cardiovascular mortality that characterizes the individuals 
with CKD, the Work Group for Kidney Disease Outcomes Quality Initiative 
(K/DOQI) published the Clinical Practice Guidelines for Managing 
Dyslipidemias in CKD Ref 89, and proposed the adoption of Adult Treatment 
Panel (ATP) III LDL-cholesterol targets Ref 90, for individuals with stage 5 
CKD. In other words, these guidelines suggested that in individuals with 
ESRD an LDL-cholesterol value lower that 100 mg/dl should be achieved.  
 
       However, the utilization of LDL cholesterol as a target for preventive 
therapy in patients with CKD has several important limitations. It is well 
known that LDL-cholesterol is commonly determined by the Friedewald 
calculation in specimens from fasting subjects and with triglyceride 
concentrations of <400 mg/dl. However, the equation is considerably 
inaccurate even at triglyceride concentrations of 200–400 mg/dl Ref 91. Thus, 
since uremic dyslipidemia is mainly characterized by increased 
concentrations of triglycerides, the use of Friedewald equation for the 
determination of LDL cholesterol values in this patient population may 
result in important measurement errors. As a consequence, it has been 
proposed that a number of different equations that take into consideration the 
serum levels of apolipoprotein B may be more appropriate in individuals 
with impaired renal function.  
 
       An alternative approach to this problem is the calculation of non-HDL-
cholesterol (total cholesterol – HDL cholesterol) values. The calculation of 
this parameter (which represents the sum of the concentrations of all 
apolipoprotein B-containing particles) overcomes the methodological 
limitations of LDLcholesterol determination, does not require fasting 
specimens Ref 92 and, most importantly, in addition to LDL particles takes 
into account the concentrations of all apolipoprotein B-containing particles 
such as LDL, Lp(a), IDL and chylomicron remnants Ref 93. Several studies 
have shown that the concentrations of these particles (that are not captured 
by conventional LDL measurement) are elevated in patients with renal 
failure and may independently contribute to the determination of future 
cardiovascular risk. The National Kidney Foundation guidelines suggest 
non-HDL-cholesterol values of < 130 mg/dl as a secondary target of therapy 
in individuals with triglyceride values of 1 200 mg/dl . 
 
       Treating high low-density lipoprotein cholesterol   for CKD patients 
with LDL 100 to 129 mg/dL it is reasonable to attempt to lower LDL to less 
than 100 mg/dL with therapeutic lifestyle changes. If after 3 months this 
target has not been reached, a statin should be added. Patients with LDL 
greater than or equal to 130 mg/dL are unlikely to reach target with diet 
alone, so diet and a statin should generally be started simultaneously. Statins 
are safe in patients with CKD, but drug interactions (eg, with macrolide 
antibiotics, azole antifungal agents, dihydropyridine calcium channel 
blockers, and cyclosporine A) should be avoided or should prompt a 
reduction in the dose of the statin. 
 
       Acute and chronic liver disease should be ruled out before initiation of a 
statin, but it is not necessary to obtain routine liver enzymes to screen for 
hepatotoxicity thereafter. Patients should be told that if they develop unusual 
muscle soreness or pain, indicating possible statin-induced myopathy. It has 
been suggested that a base line CPK be obtained to help interpret CPK levels 
when myopathy is suspected. 
 
       For patients with LDL persistently greater than or equal to 130 mg/dl 
despite diet and maximum statin therapy, consideration should be given to 
adding a second agent. For second agent, fibrates should be avoided. If 
triglycerides are not elevated then a bile acid sequestrant is an option. The 
new cholesterol absorption inhibitor ezetimibe may have fewer 
gastrointestinal adverse effects than bile acid sequestrant, and ezetimibe 
seems to be safe in patients with CKD. It is well known that statins are by 
far the most commonly prescribed hypolipidemic drugs in the general 
population, and numerous large, randomized, prospective studies have 
shown that their use is accompanied by an impressive reduction in the 
incidence of cardiovascular events Ref 94. 
 
        On the other hand, data from studies conducted in individuals with 
CKD suggest that the effect of these drugs on cardiovascular morbidity and 
mortality in this patient population is significantly influenced by the severity 
of renal dysfunction. Thus, in several large, prospective, placebo-controlled 
trials of statins, post hoc analyses of subgroups with mild to moderate renal 
failure revealed a significant reduction in cardiovascular morbidity and 
mortality Ref 95,96,97,98. The same results were also obtained by studying 
prespecified subgroups of individuals with impaired renal function in the 
HPS Ref 99, and ASCOT-LLA Ref 100, studies that utilized simvastatin and 
atorvastatin, respectively. 
 
       As a consequence, the use of statins as a first-line therapy for the 
prevention of ischemic events in dyslipidemic individuals with CKD (stages 
1–3) seems to be a safe, reasonable and evidence-based approach. 
Nevertheless, similar findings were also reported in a recent small 
Scandinavian study that showed a significant decrease in cardiovascular end 
points after atorvastatin administration in patients with predialysis renal 
failure but no effect in individuals who were on maintenance HD Ref 101. 
 
         Several mechanisms have been proposed for the explanation of the 
failure of statins to improve cardiovascular outcomes in individuals with 
advanced renal failure. Thus, it has been suggested that the development of 
atherosclerosis in this population may have a different athophysiological 
basis (arterial wall calcification, inflammation, etc.), whereas other 
investigators emphasized that lipoproteins other than LDL (such as Lp(a), 
IDL, etc.) may play a significant role in the initiation and progression of 
coronary atherosclerosis Ref 102.  
       Finally, it has been proposed that the beneficial effect of statins may be 
confounded by the presence of micro-inflammation and/or malnutrition in 
individuals with ESRD. Whatever the cause, and while awaiting the results 
of ongoing statin trials in this patient population, we believe that the decision 
for the administration of statins in HD patients should be individualized. It is 
well known that fibrates reduce the concentrations of triglycerides, increase 
the serum concentrations of HDL-cholesterol and induce a shift in the LDL 
subfraction distribution towards larger and more buoyant particles.  
 
       Thus, these drugs could represent an ideal option for the treatment of 
uremic dyslipidemia. However, it has been shown that the administration of 
fibrates (possibly with the exception of gemfibrozil) in individuals with 
impaired renal function is associated with an extremely high risk of 
muscular toxicity Ref 103,104. In addition, these drugs also significantly 
increase serum Creatinine values. Although it has been proposed that this 
increase does not represent a true deterioration in renal function but rather is 
due to increased metabolic production of creatinine. 
 
        In addition, the impact of fibrates on cardiovascular end points in 
individuals with impaired renal function has not been extensively studied.  
       Thus, although an observational study suggested that the use of fibrates       
in patients with renal failure does not reduce total mortality Ref 105, a post hoc 
analysis of the secondary prevention VAHIT study revealed that the 
administration of gemfibrozil in individuals with moderate renal failure 
reduced the risk of the primary end point (coronary death or nonfatal 
myocardial infarction) by 27% Ref 106.  
 
       In our opinion fibrates should be used only in the subpopulation of 
patients with CKD who exhibit extremely elevated triglycerides values (1 
500 mg/dl). In these cases the risk of acute pancreatitis justifies the use of 
gemfibrozil as the fibrate of choice in individuals with impaired renal 
function, although previous studies have shown that its administration in 
CKD patients may, in some cases, be followed by muscle aches and a 
significant rise in serum creatine phosphokinase values. 
 
        A number of other hypolipidemic drugs that are increasingly used in the 
general population (such as niacin –3 polyunsaturated fatty acids and 
ezetimibe) may also play important roles in the management of uremic 
dyslipidemia. However, although small studies have documented the 
efficiency and the tolerability of these substances in patients with chronic 
kidney disease, there is a lack of evidence concerning their impact on the 
cardiovascular risk in this patient population. 
 
       The patients with LDL greater than or equal to 100 mg/dl, the LDL 
should be the target of therapy. Patients with normal LDL but triglycerides 
greater than or equal to 200 mg/dl and non-HDL cholesterol greater than or 
equal to 130 mg/dl, however should be treated. The goal should be reduce 
the non-HDL cholesterol to less than 130 mg/dl.   
 
 
 
 
 
P 
                              MATERIALS AND METHODS 
 
1. This study was conducted in 50 patients of CKD in stage 3,4 and 5. They 
are selected as inpatients of Government Royapettah Hospital during 
January 2008 to August 2008. This study also included 50 people as 
control group.  
 
2. Study design: Case control study. 
 
Inclusion Criteria 
 
1. Patients with chronic kidney disease stage 3,4 and 5 on conservative 
management or dialysis irrespective of etiology except due to diabetes 
mellitus.  
2.  Patients with creatinine clearance less than 60ml/min were included. 
3. Patients with bilaterally contracted kidneys on abdomen USG with poor 
cortico medullary differentiation were included. 
                                                                                                                      
Exclusion Criteria 
 
       Patients with obesity, diabetes mellitus, past history of  coronary heart 
disease ,  patients with smoking and alcoholism , pregnancy, patients on B-
blockers and OCPs were excluded.  
 
  
       50 age and sex matched normal healthy individuals were selected as control. 
A detailed history and clinical examination were performed in all patients. Height, 
weight, BP of all patients were recorded. Apart from routine investigations blood 
urea, creatinine, electrolytes, creatinine clearance by using Cockcroft-Gault 
equation were measured.  
 
        NKF KDOQI (National Kidney Foundation- Kidney Disease Outcomes 
Quality Initiative) staging system was used to classify patients. 
       Stage 1: GFR >90 ml/min/1.73m2     
       Stage 2: GFR 60-89 ml/min/1.73m2     
       Stage 3: GFR 30-59 ml/min/1.73m2     
       Stage 4: GFR 15-29 ml/min/1.73m2     
       Stage 5: GFR <15 ml/min/1.73m2 (or dialysis). 
 
Blood pressure: 
 Right upper arm blood pressure is taken in supine position by using 
sphygmomanometer under appropriate condition. 
 
Renal function test: 
 Blood samples are collected for blood urea and serum creatinine and 
analyzed in the laboratory at GRH, Chennai.  
 
USG abdomen: 
 
       Ultrasonogram of abdomen was done for all individuals in this study. 
    
Lipid profile:  
          Blood samples were obtained on one occasion from antecubital 
venepuncture after an over night fast (12 hrs) from all patients.       
 
Triglycerides were estimated by enzymatic colorimetric method. 
TC was estimated using enzymatic method. 
HDL was estimated by phosphotungstate method. 
LDL cholesterol was calculated by Friedewald`s equation. 
                 LDL = TC - Triglycerides/5 – HDL 
 
       The VLDL was estimated by dividing the plasma Triglycerides by 5. This 
formula is used only on patients with fasting Triglycerides level of less than 
350 mg/dl. 
       According to National Cholesterol Treatment Program Adult Treatment 
Panel III guidelines, normal values are, 
       LDL cholesterol                 <130 mg/dl 
             (with 2+ risk factors) 
       HDL cholesterol                >40 mg/dl 
       Triglycerides                     <150 mg/dl 
       Total cholesterol                <200 mg/dl 
 ECG: 
       A standard 12 lead resting electrocardiogram was taken for all individuals 
in this study. 
 
Romhilt-Estes point score system Ref 107: 
       Probable left ventricular hypertrophy is diagnosed if 4 points are present 
and definite left ventricular hypertrophy is diagnosed if 5 or more points are 
present. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Romhilt-Estes point score system 
 
 
 
 
 
 
 
 
 
  
 
 
Criterion Points
Any limb R wave or S wave >/=2.0 mV (20 mm) 
   OR S in V1 or S in V2 >/= 3.0 mV (30 mm) 
   OR R in V5 or R in V6 >/= 3.0 mV (30 mm) 
3 
ST-T wave changes typical of LVH 
   Taking digitalis 
   Not taking digitalis 
  
1 
3 
Left atrial abnormality 
   P terminal force in V1 is 1 mm or more in depth with a duration 
>/= 40 ms (0.04 sec) 
3 
Left axis deviation >/= -30ª 2 
QRS duration >/= 90 ms 1 
Intrinsicoid deflection in V5 or V6 >/= 50 ms (0.05 sec) * 1 
ECG – Features of LVH 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                   Results and observation  
 
       One hundred patients took part in this study. Out of hundred patients 
fifty were known case of CKD and the remaining fifty were control. Of the 
50 CKD patients 18 were female and the remaining 32 were male. Their age 
varied from 28 to 52 yrs. All the 50 patients who took part in the study were 
found to be hypertensive at the beginning of the study. Their systolic BP 
varied from 130 to 180 mmHg and diastolic BP varied from 90 to 120 
mmHg. Of the 50 patients 34 were known hypertensive on treatment, others 
were newly detected for the first time on admission. Five patients had 
previous history of dialysis.  
 
      Eight patients had arcus senilis and on fundus examination ten patients 
showed features of hypertensive retinopathy grade 3. Xanthoma was found 
in two patients. Blood urea levels varied from 47 mg/dl to 160 mg/dl. 
Creatinine levels varied from 3 mg/dl to 12 mg/dl. 32 patients had bilateral 
contracted kidneys on ultrasonogram. In 8 patients electro cardiogram 
showed features of LVH. In 14 patients electro cardiogram showed features 
of myocardial ischemia.  
 
       Total cholesterol was above 200 mg/dl in 13(26%) patients. Serum 
triglycerides were above the upper limit of normal (150 mg/dl) in 39 (78%) 
patients. HDL was less than 40 mg/dl in 45 (90%) patients. LDL cholesterol 
was above 130 mg/dl in 14(28%) patients and above 100 mg/dl in 42(84%) 
patients. Ratio between Total cholesterol and HDL cholesterol was above 6 
in 20(40%) patients. Type 4 hyperlipidemia was present in 39 out of 50 
patients.  
 
Observations about triglycerides in this study;  
       For study group; 
           The lowest value of triglycerides in this study was 53 mg/dl. The 
highest value was 338 mg/dl. Mean triglycerides of the study group was 
197.26 mg/dl. The mean deviation was 45.51 mg/dl. The standard deviation 
was 59.75 mg/dl. The standard error of mean was 8.45. 
       For control group; 
              The lowest value of triglycerides in this control group was 72mg/dl. 
The highest value was 212 mg/dl. Mean triglycerides of the control group 
was 127.78 mg/dl. The mean deviation was 20.54 mg/dl. The standard 
deviation was 27.53 mg/dl. The standard error of mean was 3.89. 
         Statistical significance of these values was analyzed by finding out the 
standard error of difference between the two mean. The standard error of 
difference between the two mean was 9.30.  The actual difference of the 
mean between the two groups was 69.48, which is more than twice of   
standard error of difference between the two mean. The P value equals 
0.0002.   By conventional criteria, this difference is considered to be 
extremely statistically significant.  So the difference in serum triglycerides 
values between the two groups is statistically significant. 
 
Observations about HDL cholesterol in this study;  
       For study group; 
              The lowest value of HDL cholesterol in this study was 29 mg/dl. 
The highest value was 52 mg/dl. Mean HDL cholesterol of the study group 
was 34.18 mg/dl. The mean deviation was 3.46 mg/dl. The standard 
deviation was 4.62mg/dl. The standard error of mean was 0.65. 
       For control group; 
              The lowest value of HDL cholesterol in this control group was 38 
mg/dl. The highest value was 78 mg/dl. Mean HDL cholesterol of the 
control group was 52.90 mg/dl. The mean deviation was 8.82 mg/dl. The 
standard deviation was 10.41 mg/dl. The standard error of mean was 1.47. 
       Statistical significance of these values was analyzed by finding out the 
standard error of difference between the two mean. The standard error of 
difference between the two mean was 1.61.  The actual difference of the 
mean between the two groups was 18.72, which is more than twice of   
standard error of difference between the two mean. The P value is less than 
0.0001.   By conventional criteria, this difference is considered to be 
extremely statistically significant.  So the difference in serum HDL 
cholesterol values between the two groups is statistically significant. 
 
Observations about LDL cholesterol in this study;  
       For study group; 
            The lowest value of LDL cholesterol in this study was 70 mg/dl. The 
highest value was 209 mg/dl. Mean LDL cholesterol of the study group was 
118.61mg/dl. The mean deviation was 14.72 mg/dl. The standard deviation 
was 21.27mg/dl. The standard error of mean was 3.01. 
       For control group; 
            The lowest value of LDL cholesterol in this control group was 49 
mg/dl. The highest value was 154 mg/dl. Mean LDL cholesterol of the 
control group was 100.02 mg/dl. The mean deviation was 19.55 mg/dl. The 
standard deviation was 23.92 mg/dl. The standard error of mean was 3.38. 
       Statistical significance of these values was analyzed by finding out the 
standard error of difference between the two mean. The standard error of 
difference between the two mean was 4.53.  The actual difference of the 
mean between the two groups was 18.59, which is more than twice of   
standard error of difference between the two mean. The P value equals 
0.0005.   By conventional criteria, this difference is considered to be 
extremely statistically significant. So the difference in serum LDL 
cholesterol values between the two groups is statistically significant. 
 
Observations about total cholesterol in this study;  
       For study group; 
             The lowest value of total cholesterol in this study was 125 mg/dl. 
The highest value was 276 mg/dl. Mean total cholesterol of the study group 
was 192.24mg/dl. The mean deviation was 14.64 mg/dl. The standard 
deviation was 22.55mg/dl. The standard error of mean was 3.19. 
     For control group; 
            The lowest value of total cholesterol in this control group was 141 
mg/dl. The highest value was 230 mg/dl. Mean total cholesterol of the 
control group was 178.48 mg/dl. The mean deviation was 16.66 mg/dl. The 
standard deviation was 20.34 mg/dl. The standard error of mean was 2.88. 
         Statistical significance of these values was analyzed by finding out the 
standard error of difference between the two mean. The standard error of 
difference between the two mean was 4.29.  The actual difference of the 
mean between the two groups was 13.76, which is more than twice of   
standard error of difference between the two mean. The P value equals 
0.0019.   By conventional criteria, this difference is considered to be very 
statistically significant.  So the difference in serum total cholesterol values 
between the two groups is statistically significant. 
 
Ratio between total cholesterol and HDL cholesterol 
        The ratio between total cholesterol and HDL cholesterol is considered 
as a risk factor for coronary artery disease, when the value exceeds 6.  In this 
study 20 out of 50 patients were found to have more than 6.   
 
        For study group; 
               The lowest value of ratio between total cholesterol and HDL 
cholesterol in this study was 3.37. The highest value was 7.88. Mean ratio 
between total cholesterol and HDL cholesterol of the study group was 5.7. 
The mean deviation was 0.8. The standard deviation was 1.0. The standard 
error of mean was 0.1. 
  
       For control group; 
             The lowest value of ratio between total cholesterol and HDL 
cholesterol in this control group was 2.3. The highest value was 5.4. Mean 
ratio between total cholesterol and HDL cholesterol of the control group was 
3.5. The mean deviation was 0.7. The standard deviation was 0.9. The 
standard error of mean was 0.1. 
 
           Statistical significance of these values was analyzed by finding out 
the standard error of difference between the two mean. The standard error of 
difference between the two mean was 0.19.  The actual difference of the 
mean between the two groups was 2.2, which is more than twice of   
standard error of difference between the two mean. The P value is less than 
0.0001.   By conventional criteria, this difference is considered to be 
extremely statistically significant. So the difference in ratio between total 
cholesterol and HDL cholesterol between the two groups is statistically 
significant.  
 
       All the 20 patients with ratio of TC to HDL-C of more than 6 were 
having Creatinine clearance of less than 29ml/min i.e, stage 4 and 5 CKD.In 
Peritoneal Dialysis patients, both total cholesterol and LDL cholesterol are 
within normal limits whereas HDL cholesterol is decreased. It was found 
that the serum concentration of increased triglycerides, decreased HDL 
cholesterol ,increased LDL  cholesterol ,increased total  cholesterol  were 
statistically significant in CKD patients stage 3,4 and 5. 
 
 
P 
                                      Discussion 
       The incidence and prevalence of chronic kidney disease (CKD) are 
increasing worldwide and are associated with poor outcomes. CVD as the 
major cause of mortality in patients with mild to moderate CKD and end- stage 
renal disease (ESRD). Approximately 50% of patients with ESRD die from a 
cardiovascular event, which indicates a cardiovascular mortality that is 30 
times higher in dialysis patients and 500 times higher in 25- to 34-year-old 
ESRD patients than in individuals from the general population of the same age 
and race. Premature CVD extends from mild to moderate stages of CKD. 
 
        Vaziri ND, Moradi H et al study states that the most common quantitative 
lipid abnormalities in predialysis CKD patients are hypertriglyceridemia, 
increased concentrations of triglyceride-rich lipoprotein remnants, reduced 
high-density lipoprotein (HDL)-cholesterol levels as well as increased 
concentrations of lipoprotein(a) (Lp(a))Ref 108. Notably, total and LDL-
cholesterol levels are usually within normal limits or slightly reduced in these 
individuals. 
 
        Liu Y, Coresh J, Eustace JA, et al reported in their study that the typical 
profile of patients with chronic kidney disease, that is, the constellation of 
moderate elevation of plasma triglyceride concentrations, combined with low 
plasma HDL-cholesterol, corresponds to the pattern of dyslipidemia type IV 
according to Frederickson et al. In CKD, total cholesterol is usually normal or 
even low. This may be the result of an additional microinflammatory state 
and/or malnutrition Ref 109. 
 
        In our study, lipid profile shows increased plasma triglyceride   
concentrations, combined with low plasma HDL-cholesterol as similar with 
that of Vaziri ND, Moradi H et al and Liu Y, Coresh J, Eustace JA, et al study 
but, total cholesterol and, LDL-cholesterol were increased. 
 
        The most common type of dyslipidemia observed in Liu Y, Coresh J, 
Eustace JA, et al study was type IV according to Frederickson et al.Ref 110 
Similar reports were observed by Bagdade JD, Yee E, Wilson D, and Shafrir E 
et al Ref 111. Also in our study the most common type of dyslipidemia is type IV 
according to Frederickson. 
 
        Plasma triglyceride concentration is frequently elevated in patients and 
experimental animals with CRF. However, plasma cholesterol concentration is 
usually normal, even reduced, and only occasionally elevated in patients with 
end-stage renal disease (ESRD). Elevation of plasma triglycerides in ESRD 
patients is accompanied by increased plasma concentration and impaired 
clearance of VLDL. This is associated with the accumulation of atherogenic 
VLDL remnants, commonly known as IDL. Similarly, clearance of 
chylomicrons is impaired and plasma concentration of chylomicron remnants is 
elevated in CRF patients. In contrast, plasma concentration of LDL is usually 
normal and only occasionally elevated in ESRD patients. Plasma HDL 
concentration is consistently reduced Ref 112. 
 
        In addition to the quantitative abnormalities cited above, the composition 
of plasma lipoproteins is altered in CRF Ref 113. For instance, the cholesterol 
content of VLDL is relatively increased and its triglyceride content is   
relatively reduced in CRF. In contrast, CRF results in a relative reduction in 
cholesterol and relative increase in the triglyceride content of LDL. Similarly, 
cholesterol ester and free cholesterol content of HDL are consistently reduced, 
whereas its triglyceride content is elevated, in CRF. The above compositional 
abnormalities are present in nearly all patients with mild to severe renal 
insufficiency (even those with normal plasma total cholesterol and triglyceride 
levels) and point to redistribution of cholesterol from HDL to VLDL and ID 
and defective removal of triglycerides from   LDL and HDL particles. 
        The most common lipid abnormality in our study is decreased HDL in 
74% of patients. Similar observation has been reported by Burrell et al. HDL –
cholesterol was found to have a positive correlation with creatinine clearance 
by grutz macher et al. LCAT plays an important role in HDL-mediated 
cholesterol uptake from the extrahepatic tissues. LCAT deficiency can 
potentially account for diminished plasma HDL cholesterol and impaired HDL 
maturation in CRF. 
 
       CETP mediates transfer of cholesterol ester from HDL to IDL in exchange 
for triglycerides. Thus a potential increase in plasma CETP can contribute to 
the CRF-associated reduction in HDL cholesterol ester and elevation of HDL 
triglycerides. In fact, according to a recent study, more than 34% of 
hemodialysis-dependent patients were found to have high plasma CETP levels 
Ref 114. 
 
        Hepatic lipase catalyzes hydrolysis and removal of the triglyceride content 
of HDL. Thus hepatic lipase deficiency can potentially contribute to increased 
HDL triglyceride content. CRF results in pronounced hepatic lipase deficiency 
in humans. 
          Hypertriglyceridemia is a common feature of CRF Ref 115 and causes 
include increased synthesis and/or diminished clearance from the circulation. 
Because renal insufficiency causes insulin resistance, which can, in turn, 
promote hepatic VLDL production, it has been suggested that increased 
production may be responsible, in part, for CRF-associated elevations in 
plasma VLDL and triglycerides. 
 
       The relationship between total cholesterol and atherosclerotic CAD is 
curvilinear according to the Multiple Risk Factor Intervention Trial               
(MRFIT) .If a risk ratio of 1.0 is arbitrarily assigned at a total cholesterol level 
of 200 mg/dl, the risk ratio increased to 2 at 250 mg/dl and 4 at 300   mg/dl. 
The Cholesterol Lowering Atherosclerotic Study (CLAS) demonstrated the 
benefit of cholesterol lowering even in patient with normal or moderately 
increased cholesterol level. 
 
       Although desirable blood Cholesterol value may be below 200 mg/dl or 
even much lower at 150 mg/dl, it needs reemphasizing that the cholesterol 
level is only part of the patient’s absolute global risk.  
 
         LDL-cholesterol values above 130 mg/dl despite diet warrant drug 
therapy in those at medium risk, while in those at highest risk with CHD or   
equivalents, the goal is less than 100 mg/dl or less than 70 mg/dl in some   
cases. The calculation of non-HDL-cholesterol (total cholesterol – HDL 
cholesterol) values represents the sum of the concentrations of all 
apolipoprotein B-containing particles, overcomes the methodological 
limitations of LDL cholesterol determination, does not require fasting 
specimens  and, most importantly, in addition to LDL particles takes into 
account the concentrations of all apolipoprotein B-containing particles such as 
VLDL, Lp(a), IDL and chylomicron remnants . 
 
        Several studies have shown that the concentrations of these particles (that 
are not captured by conventional LDL measurement) are elevated in patients 
with renal failure and may independently contribute to the determination of 
future cardiovascular risk Ref 116,117. The National Kidney Foundation guidelines 
suggest non-HDL-cholesterol values of 130 mg/dl as a secondary target of 
therapy in individuals with triglyceride values of 1 200 mg/dl . Usually a U- or 
J-shaped relationship was noted between plasma cholesterol concentration and 
cardiovascular mortality i.e., a higher mortality at low as well as high plasma 
cholesterol concentrations .The most plausible explanation for this paradox is 
that this represents an example of reverse epidemiology Ref 118,119, i.e., a 
relationship, which is reversed by a confounding factor. The recent work of Liu 
et al. Ref 120, is important in this respect. They identified microinflammation as a 
confounding factor. 
 
       Patients with CKD are at high risk for developing CVD. Most CKD 
patients have a 10 year risk of coronary heart disease events greater than or 
equal to 20%, placing them in the hightest risk category according to the 
national cholesterol education program adult treatment panel 3   guidelines.Ref 
121. Meta analysis of 13 small prospective studies revealed a significant 
reduction in the rate of decline in the glomerular filtration rate (GFR) and 
marginal reductions in proteinuria and progression toward ESRD with lipid-
lowering therapy primarily with various statins Ref 122 . 
 
       Similarly, the Heart Protection Study showed a significantly lower rate of 
rise in serum creatinine concentration in the statin-treated group compared with 
the placebotreated group Ref 123. Also, in a large study of patients with coronary 
heart disease and dyslipidemia, statin administration for 3 yr resulted in a 
significant improvement in creatinine clearance compared with a placebo 
group.  
         However, among patients with a baseline GFR below 40 ml/min, statin 
administration was associated with a significantly lower rate of decline in 
estimated GFR. The beneficial effects of statins have been attributed to both 
the lipid-lowering and lipid-independent anti-inflammatory (via interference 
with isoprenylation processes) action of these drugs. 
 
        Dyslipidemia represents an integral component of CKD. Disturbances in 
lipoprotein metabolism (mainly accumulation of intact or partially metabolized 
apolipoprotein B-containing particles as well as reduced concentrations of 
HDL-cholesterol) are evident even at the early stages of CKD and usually 
follow a downhill course that parallels the deterioration in renal function. Since 
several intrinsic (genetic, primary kidney disease) or exogenous (drugs, method 
of renal replacement) factors can influence the phenotypic expression of these 
alterations, the precise knowledge of the pathophysiological mechanisms that 
underlie their development is of paramount importance. 
         Recently published studies indicate that dyslipidemia in these patients 
may actively participate in the pathogenesis of CVD as well as in the 
deterioration of renal function. Thus, we believe that the current evidence 
dictates the use of statins in patients with mild to moderate CKD. On the other 
hand, in subjects with ESRD the decision for the institution of lipid-lowering 
therapy should be individualized.  
 
        Thus, in individuals with established CVD as well as in those who run a 
high risk for acute pancreatitis due to severe hypertriglyceridemia, the 
administration of hypolipidemic drugs (statins and gemfibrozil respectively) is 
a safe and reasonable approach. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                 Conclusion 
 
1. Most common lipid abnormality in this study is statistically 
significant reduction of HDL-Cholesterol level in patients with 
Chronic Kidney Disease stage 3,4 and 5 . 
2. There is a statistically significant increase in serum triglycerides level 
in patients with CKD stage 3,4 and 5. 
3.  There is a statistically significant increase in serum LDL-Cholesterol 
and Total Cholesterol level in patients with CKD stage 3,4 and 5  . 
4. There is a negative correlation between serum HDL-Cholesterol and 
severity of renal failure.  
5. There is a positive correlation between the ratio of Total Cholesterol 
to HDL-Cholesterol and severity of CKD.  
6. In Peritoneal Dialysis patients, both Total Cholesterol and LDL-
Cholesterol are within normal limits whereas HDL- Cholesterol is 
decreased. 
7.  Systemic hypertension is statistically associated with CKD. 
 
 
 
 
  
                                         Bibliography 
 
1. National Kidney Foundation KD; Clinical practice guidelines for chronic 
kidney disease; Evaluation, classification and stratification. Am J 
Kidney Dis2002; 39; S1- S266. 
2. Effects of diet and antihypertensive therapy on creatinine clearance and 
serum creatinine concentration in the Modification of Diet in Renal 
Disease Study.J AM Soc Nephrol 1996; 7;556-66. 
3. Jacobsen FK, Christensen CK, et al. Pronounced increase in serum 
creatinine concentration after eating cooked meat. BMJ 1979;1;1049-50. 
4. Mayersohn M,Conrad KA, Achari R. The influence of a cooked meat 
meal on serum creatinine concentration and creatinine clearance. Br J 
Clin Pharmacol 1983;15;227-30. 
5. Jones JD, Burnett PC. Creatinine metabolism in humans with decreased 
renal function; creatinine deficit. Clin Chem. 1974;20; 1204. 
6. Hankins DA,Babb AL,et al. Creatinine degradation I; the kinetics of 
creatinine removal in patients with chronic kidney disease; Int J Artif 
Organs 1981;4;35-9. 
7. Levey AS, Beto JA,Coronada BE, et al . Controlling the epidemic of 
cardiovascular disease in chronic kidney disease; National Kidney 
  
Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 
1988;32: 853-906. 
8. Diamond JR. Analogous pathobiologic mechanisms in 
glomerulosclerosis and atherosclerosis. Kidney Int Suppl 1991;31: S29-
34. 
9. Attman PO, Samuelsson O, Alaupovic P. ipoprotein metabolism and 
renal failure. Am J Kidney Dis 1933;21:573-92.  
10. Keane WF. Lipids and the Kidney. Kidney Int 1994;46:910-20. 
11. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, and Holman 
     RR. Development and progression of nephropathy in type 2 diabetes:   
     the United Kingdom Prospective Diabetes Study (UKPDS 64),  
     Kidney Int 63: 225–232, 2003. 
12. Foley RN, Parfrey PS, and Sarnak MJ. Clinical epidemiology of 
cardiovascular disease in chronic renal disease. Am J Kidney Dis 32: 
S112–S119, 1998 
13. Keith DS, Nichols GA, Gullion CM, Brown JB, and Smith DH. 
Longitudinal follow-up and outcomes among a population with chronic 
kidney disease in a large managed care organization. Arch Intern Med 
164: 659–663, 2004. 
  
14. Himmelfarb J, Stenvinkel P, Ikizler TA, and Hakim RM. The elephant 
in uremia: oxidant stress as a unifying concept of cardiovascular disease 
in uremia. Kidney Int 62: 1524–1538, 2002. 
15. McCullough PA. Why is chronic kidney disease the “spoiler” for 
cardiovascular outcomes? J Am Coll Cardiol 41: 725–728, 2003. 
16. Stenvinkel P and Alvestrand A. Inflammation in end-stage renal 
disease: sources, consequences, and therapy. Semin Dial 15: 329–337, 
2002. 
17. Vaziri ND. Effect of chronic renal failure on nitric oxide metabolism. 
Am J Kidney Dis 38: S74–S79, 2001. 
18. Sarnak MJ, Levey AS, Schoolwerth AC,Coresh J, Culleton B, Hamm 
LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, 
Pfeffer M, Raij L, Spinosa DJ, Wilson PW: Kidney disease as a risk 
factor for development of cardiovascular disease: a statement from the 
American Heart Association Councils on Kidney in Cardiovascular 
Disease, High Blood Pressure Research, Clinical Cardiology, and 
Epidemiology and Prevention. Circulation 2003; 108: 2154–2169. 
19. Hallan SI, Coresh J, Astor BC, Asberg A, Powe NR, Romundstad S, 
Hallan HA, Lydersen S, Holmen J: International comparison of the 
  
relationship of chronic kidney disease prevalence and ESRD risk. J Am 
Soc Nephrol 2006; 17: 2275–2284. 
20. Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of 
cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 
32:S112–S119. 
21. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney 
disease and the risks of death, cardiovascular events, and hospitalization. 
N Engl J Med 2004; 351: 1296–1305. 
22. Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, 
Qizilbash N, Peto R,Collins R: Blood cholesterol and vascular mortality 
by age, sex, and blood pressure: a meta-analysis of individual data from 
61 prospective studies with 55,000 vascular deaths. Lancet 2007; 370: 
1829–1839. 
23. Vaziri ND: Dyslipidemia of chronic renal failure: the nature, 
mechanisms, and potential consequences. Am J Physiol Renal Physiol  
    2006; 290:F262–F272.  
24. Fliser D, Pacini G, Engelleiter R, Kautzky- Willer A, Prager R, Franek 
E, Ritz E: Insulin resistance and hyperinsulinemia are already present in 
patients with incipient renal disease. Kidney Int 1998; 53: 1343–1347. 
  
25. Sechi LA, Catena C, Zingaro L, Melis A, De Marchi S: Abnormalities of 
glucose metabolism in patients with early renal failure. Diabetes 2002; 
51: 1226–1232. 
26. Charlesworth JA, Kriketos AD, Jones JE, Erlich JH, Campbell LV, 
Peake PW: Insulin resistance and postprandial triglyceride levels in 
primary renal disease. Metabolism 2005; 54: 821–828. 
27. Prinsen BH, de Sain-van der Velden MG, de Koning EJ, Koomans HA, 
Berger R, Rabelink TJ: Hypertriglyceridemia in patients with chronic 
renal failure: possible mechanisms. Kidney Int Suppl 2003; 84:S121–
S124. 
28. Vaziri ND, Liang K: Down-regulation of tissue lipoprotein lipase 
expression in experimental chronic renal failure. Kidney Int 1996; 50: 
1928–1935. 
29. Vaziri ND, Liang K, Parks JS: Down-regulation of hepatic 
lecithin:cholesterol acyltransferase gene expression in chronic renal 
failure. Kidney Int 2001; 59: 2192–2196. 
30. Mori Y, Hirano T, Nagashima M, Shiraishi Y, Fukui T, Adachi M: 
Decreased peroxisome proliferator-activated receptor alpha gene 
expression is associated with dyslipidemia in a rat model of chronic 
renal failure. Metabolism 2007; 56: 1714–1718. 
  
31. Lee DM, Knight-Gibson C, Samuelsson O, Attman PO, Wang CS, 
Alaupovic P: Lipoprotein particle abnormalities and the impaired 
lipolysis in renal insufficiency. Kidney Int 2002; 61: 209–218. 
32. Cheung AK, Parker CJ, Ren K, Iverius PH: Increased lipase inhibition in 
uremia: identification of pre-beta-HDL as a major inhibitor in normal 
and uremic plasma. Kidney Int 1996; 49: 1360–1371. 
33. Akmal M, Kasim SE, Soliman AR, Massry SG: Excess parathyroid 
hormone adversely affects lipid metabolism in chronic renal failure. 
Kidney Int 1990; 37: 854–858.  
34. Vaziri ND, Wang XQ, Liang K: Secondary hyperparathyroidism 
downregulates lipoprotein lipase expression in chronic renal failure. Am 
J Physiol 1997; 273:F925–F930. 
35. Akmal M, Perkins S, Kasim SE, Oh HY, Smogorzewski M, Massry SG: 
Verapamil prevents chronic renal failure-induced abnormalities in lipid 
metabolism.Am J Kidney Dis 1993; 22: 158–163. 
36. Nishizawa Y.Shoji T .Kawagishi T, et al. atherosclerosis in uremia; 
possible roles of hyperparathyrpidism and intermediate density 
lipoprotein accumulation. Kidney Int Suppl 1997; 62;S 90-2.  
37. Arnadottir M, Nilsson- Ehle P. Lipid metabolism in chronic renal failure. 
Nephrol Dial Transplant 1995; 10; 2381-2 
  
38. Despres JP, Lemieux I, Dagenais GR, Cantin B, Lamarche B: HDL-
cholesterol as a marker of coronary heart disease risk: the Quebec 
cardiovascular study. Atherosclerosis 2000; 153: 263–272. 
39. Kontush A, Chapman MJ: Antiatherogenic small, dense HDL – 
guardian angel of the arterial wall? Nat Clin Pract Cardiovasc Med 2006; 
3: 144–153. 
40. Attman PO, Samuelsson O, Alaupovic P: Lipoprotein metabolism and 
renal failure.Am J Kidney Dis 1993; 21: 573–592. 
41. Vaziri ND, Deng G, Liang K: Hepatic HDL receptor, SR-B1 and Apo A-
I expression in chronic renal failure. Nephrol Dial Transplant 1999; 14: 
1462–1466. 
42. Guarnieri GF, Moracchiello M, Campanacci L, Ursini F, Ferri L, 
Valente M, Gregolin C: Lecithin-cholesterol acyltransferase (LCAT) 
activity in chronic uremia. Kidney Int Suppl 1978; 8:S26–S30. 
43. Kimura H, Miyazaki R, Imura T, Masunaga S, Suzuki S, Gejyo F, 
Yoshida H: Hepatic lipase mutation may reduce vascular disease 
prevalence in hemodialysis patients with high CETP levels. Kidney Int 
2003; 64: 1829– 1837. 
  
44. Dirican M, Akca R, Sarandol E, Dilek K: Serum paraoxonase activity in 
uremic predialysis and hemodialysis patients. J Nephrol 2004; 17: 813–
818. 
45. Liberopoulos EN, Papavasiliou E, Miltiadous GA, Cariolou M, 
Siamopoulos KC, Tselepis AD, Elisaf MS: Alterations of paraoxonase 
and platelet-activating factor acetylhydrolase activities in patients on 
peritoneal dialysis. Perit Dial Int 2004; 24: 580– 589. 
46. Attman PO, Samuelsson O, and Alaupovic P. Lipoprotein metabolism 
and renal failure. Am J Kidney Dis 21: 573–592, 1993.  
47. Bagdade J, Casaretto A, and Albers J. Effects of chronic uremia, 
hemodialysis, and renal transplantation on plasma lipids and lipoproteins 
in man. J Lab Clin Med 87: 38–48, 1976. 
48. Bagdade JD, Porte D Jr, and Bierman EL. Hypertriglyceridemia: a 
metabolic consequence of chronic renal failure. N Engl J Med 279: 181–
185, 1968. 
49. Heuck CC, Liersch M, Ritz E, Stegmeier K, Wirth A, and Mehls O. 
Hyperlipoproteinemia in experimental chronic renal insufficiency in the 
rat. Kidney Int 14: 142–150, 1978. 
50. Nishizawa Y, Shoji T, Kakiya R, et al. Non-high-density lipoprotein 
cholesterol (non-HDL-C) as a predictor of cardiovascular mortality in 
  
patients with end-stage renal disease. Kidney Int 2003;63:S117.  
51. Belani SS, Goldberg AC, Coyne DW. Ability of non-high-density 
lipoprotein cholesterol and calculated intermediate-density lipoprotein to 
identify nontraditional lipoprotein subclass risk factors in dialysis 
patients. Am J Kidney Dis 2004;43:320.  
52. Milionis HJ, Elisaf MS, Tselepis A, Bairaktari E, Karabina SA, 
Siamopoulos KC: Apolipoprotein(a) phenotypes and lipoprotein 
concentrations in patients with renal failure.Am J Kidney Dis 1999; 33: 
1100– 1106. 
53. Kronenberg F, Trenkwalder E, Lingenhel A, Friedrich G, Lhotta K, 
Schober M, Moes N, Konig P, Utermann G, Dieplinger H: Renovascular 
arteriovenous differences in Lp[a] plasma concentrations suggest 
removal of Lp[a] from the renal circulation. J Lipid Res 1997; 38: 1755–
1763. 
54. Kostner KM, Maurer G, Huber K, Stefenelli T, Dieplinger H, Steyrer E, 
Kostner GM: Urinary excretion of apo(a) fragments. Role in apo(a) 
catabolism. Arterioscler Thromb Vasc Biol 1996; 16: 905–911. 
55. Haffner SM, Gruber KK, Aldrete G Jr, Morales PA, Stern MP, Tuttle 
KR: Increased lipoprotein (a) concentrations in chronic renal failure. J 
Am Soc Nephrol 1992; 3: 1156– 1162. 
  
56. Bairaktari E, Elisaf M, Tsolas O, Siamopoulos KC: Serum Lp(a) levels 
in patients with moderate renal failure. Nephron 1998; 79: 367–368. 
57. Trenkwalder E, Gruber A, Konig P, Dieplinger H, Kronenberg F: 
Increased plasma concentrations of LDL-unbound apo(a) in patients 
with end-stage renal disease. Kidney Int 1997; 52: 1685–1692. 
58. Oi K, Hirano T, Sakai S, et al. Role of hepatic lipase in intermediate-
density lipoprotein and small, dense low-density lipoprotein formation in 
hemodialysis patients. Kidney Int 1999;71:S227. 
59. Joven J, Vilella E, Ahmad S, et al. Lipoprotein heterogeneity in end-
stage renal disease. Kidney Int 1993;43:410.  
60. Shoji T, Nishizawa Y, Kawagishi T, et al. Atherogenic lipoprotein 
changes in the absence of hyperlipidemia in patients with chronic renal 
failure treated by hemodialysis Atherosclerosis 1997;131:229.  
61. Nordestgaard BG, Tybjaerg-Hansen A. IDL, VLDL, chylomicrons and 
atherosclerosis. Eur J Epidemiol 1992;8:92 
62. Yu KC, Cooper AD. Postprandial lipoproteins and atherosclerosis. Front 
Biosci. 2001;6:D332. 
63. Weintraub M, Burstein A, Rassin T, et al. Severe defect in clearing 
postprandial chylomicron remnants in dialysis patients. Kidney Int 
1992;42:1247 
  
64. Rajman I, Harper L, McPake D, Kendall MJ, Wheeler DC: Low-density 
lipoprotein subfraction profiles in chronic renal failure. Nephrol Dial 
Transplant 1998; 13: 2281– 2287. 
65. Deighan CJ, Caslake MJ, McConnell M, Boulton-Jones JM, Packard CJ: 
Atherogenic lipoprotein phenotype in end-stage renal failure: origin and 
extent of small dense lowdensity lipoprotein formation. Am J Kidney 
Dis 2000; 35: 852–862. 
66. St Pierre AC, Cantin B, Dagenais GR, Mauriege P, Bernard PM, 
Despres JP, Lamarche B: Low-density lipoprotein subfractions and the 
long-term risk of ischemic heart disease in men: 13-year follow-up data 
from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol 
2005; 25: 553–559. 
67. Vaziri ND. Molecular mechanisms of lipid dysregulation in nephritic 
syndrome. Kidney Int 63: 1964–1976, 2003. 
68. Brunskill NJ. Albumin signals the coming of age of proteinuric 
nephropathy. J Am Soc Nephrol 15: 504–505, 2004. 
69. Magil AB. Interstitial foam cells and oxidized lipoprotein in human 
glomerular disease. Mod Pathol 12: 33–40, 1999. 
70. Lee HS, Lee JS, Koh HI, and Ko KW. Intraglomerular lipid deposition 
in routine biopsies. Clin Nephrol ,36: 67–75, 1991. 
  
71. Moorhead JF, Wheeler DC, and Varghese Z. Glomerular structures and 
lipids in progressive renal disease. Am J Med 87: 12N–20N, 1989. 
72. Wheeler DC and Chana RS. Interactions between lipoproteins, 
glomerular cells and matrix. Miner Electrolyte Metab 19: 149–164, 
1993. 
73. Coritsidis G, Rifici V, Gupta S, Rie J, Shan ZH, Neugarten J, and 
Schlondorff D. Preferential binding of oxidized LDL to rat glomeruli in 
vivo and cultured mesangial cells in vitro. Kidney Int 39: 858–866, 
1991. 
74. Gupta S, Rifici V, Crowley S, Brownlee M, Shan Z, and Schlondorff. 
Interactions of LDL and modified LDL with mesangial cells and matrix. 
Kidney Int 41: 1161–1169, 1992. 
75. Rovin BH and Tan LC. LDL stimulates mesangial fibronectin 
production and chemoattractant expression. Kidney Int 43: 218–225, 
1993. 
76. Hunsicker LG, Adler S, Caggiula A, England BK, Greene T, Kusek JW, 
Rogers NL, and Teschan PE. Predictors of the progression of renal 
disease in the Modification of Diet in Renal Disease Study. Kidney Int 
51: 1908–1919, 1997. 
  
77. Schaeffner ES, Kurth T, Curhan GC, Glynn RJ, Rexrode KM, Baigent 
C, Buring JE, and Gaziano JM. Cholesterol and the risk of renal 
dysfunction in apparently healthy men. J Am Soc Nephrol 14: 2084–
2091, 2003. 
78. Kuivenhoven JA, Pritchard H, Hill J, Frohlich J, Assmann G, and 
Kastelein J. The molecular pathology of lecithin: cholesterol 
acyltransferase (LCAT) deficiency syndrome. J Lipid Res 38: 191–205, 
1997. 
79. Iseki K, Yamazato M, Tozawa M, and Takishita S. Hypocholesterolemia 
is a significant predictor of death in a cohort of chronic hemodialysis 
patients. Kidney Int 61: 1887–1893, 2002. 
80. Kalantar-Zadeh K, Fouque D, and Kopple JD. Outcome research, 
nutrition, and reverse epidemiology in maintenance dialysis patients. J 
Ren Nutr 14: 64–71, 2004. 
81. Liu Y, Coresh J, Eustace JA, Longenecker JC, Jaar B, Fink NE, Tracy 
RP, Powe NR, and Klag MJ. Association between cholesterol level and 
mortality in dialysis patients: role of inflammation and malnutrition. 
JAMA 291: 451–459, 2004. 
  
82. Degoulet P, Legrain M, Reach I, et al. Mortality risk factors in patients 
treated by chronic hemodialysis. Report of the Diaphane collaborative 
study. Nephron 1982;31:103. 
83. Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive 
value of commonly measured variables and an evaluation of death rate 
differences between facilities. Am J Kidney Dis 1990;15:458.  
84. Iseki K, Yamazato M, Tozawa M, et al. Hypocholesterolemia is a 
significant predictor of death in a cohort of chronic hemodialysis 
patients. Kidney Int 2002;61:1887 
85. Magnus P, Beaglehole R: The real contribution of the major risk factors 
to the coronary epidemics: time to end the ‘only-50%’ myth. Arch Intern 
Med 2001; 161: 2657–2660. 
86. Sarnak MJ, Coronado BE, Greene T, Wang SR, Kusek JW, Beck GJ, 
Levey AS: Cardiovascular disease risk factors in chronic renal 
insufficiency. Clin Nephrol 2002; 57: 327–335. 
87. Weiner DE, Tighiouart H, Elsayed EF, Griffith JL, Salem DN, Levey 
AS, Sarnak MJ:  The Framingham predictive instrument in chronic 
kidney disease. J Am Coll Cardiol 2007; 50: 217–224. 
88. Attman PO, Samuelsson OG, Moberly J, Johansson AC, Ljungman S, 
Weiss LG, Knight- Gibson C, Alaupovic P: Apolipoprotein Bcontaining 
  
lipoproteins in renal failure: the relation to mode of dialysis. Kidney Int 
1999; 55: 1536–1542. 
89. K/DOQI clinical practice guidelines for management of dyslipidemias 
in patients with kidney disease. Am J Kidney Dis 2003; 41:I–IV, S1–
S91. 
90. Executive Summary of  The Third Report of The National Cholesterol 
Education Program (NCEP) Expert Panel on Detection, Evaluation, and 
Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel 
III). JAMA 2001; 285: 2486–2497. 
91. Bairaktari ET, Seferiadis KI, Elisaf MS: Evaluation of methods for the 
measurement of low-density lipoprotein cholesterol. J Cardiovasc 
Pharmacol Ther 2005; 10: 45–54. 
92. Desmeules S, Arcand-Bosse JF, Bergeron J, Douville P, Agharazii M: 
Nonfasting nonhigh- density lipoprotein cholesterol is adequate for lipid 
management in hemodialysis patients.Am J Kidney Dis 2005; 45: 1067–
1072. 
93. Belani SS, Goldberg AC, Coyne DW: Ability of non-high-density 
lipoprotein cholesterol and calculated intermediate-density lipoprotein to 
identify nontraditional lipoprotein subclass risk factors in dialysis 
patients.Am J Kidney Dis 2004; 43: 320–329. 
  
94. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, 
Kirby A, Sourjina T, Peto R, Collins R, Simes R: Efficacy and safety of 
cholesterol-lowering treatment: prospective meta-analysis of data from 
90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 
1267–1278. 
95. Lemos PA, Serruys PW, de Feyter P, Mercado NF, Goedhart D, Saia F, 
Arampatzis CA, Soares PR, Ciccone M, Arquati M, Cortellaro M, 
Rutsch W, Legrand V: Long-term fluvastatin reduces the hazardous 
effect of renal impairment on four-year atherosclerotic outcomes (a LIPS 
substudy). Am J Cardiol 2005; 95: 445–451. 
96. Tonelli M, Moye L, Sacks FM, Kiberd B, Curhan G: Pravastatin for 
secondary prevention of cardiovascular events in persons with mild 
chronic renal insufficiency. Ann Intern Med 2003; 138: 98–104. 
97. Tonelli M, Isles C, Curhan GC, Tonkin A, Pfeffer MA, Shepherd J, 
Sacks FM, Furberg C, Cobbe SM, Simes J, Craven T, West M: Effect of 
pravastatin on cardiovascular events in people with chronic kidney 
disease.Circulation 2004; 110: 1557–1563. 
98. Holdaas H, Wanner C, Abletshauser C, Gimpelewicz C, Isaacsohn J: 
The effect of fluvastatin on cardiac outcomes in patients with moderate 
  
to severe renal insufficiency: a pooled analysis of double-blind, 
randomized trials. Int J Cardiol 2007; 117: 64– 74. 
99. MRC/BHF Heart Protection Study of antioxidant vitamin 
supplementation in 20,536 high-risk individuals: a randomised placebo- 
controlled trial. Lancet 2002; 360: 23– 33. 
100. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, 
Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, 
Nieminen M, O’Brien E, Ostergren J: Prevention of coronary and stroke 
events with atorvastatin in hypertensive patients who have average or 
lower-than-average cholesterol concentrations, in the Anglo-
Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT-
LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 
1149–1158. 
101. Holmberg B, Brannstrom M, Bucht B, Crougneau V, Dimeny E,  
Ekspong A, Granroth B, Grontoft KC, Hadimeri H, Ingman B, Isaksson B, 
Johansson G, Lindberger K, Lundberg L, Mikaelsson L, Olausson E, 
       Persson B, Welin D, Wikdahl AM, Stegmayr BG: Safety and efficacy of  
       atorvastatin in patients with severe renal dysfunction. Scand J Urol  
       Nephrol 2005; 39: 503–510. 
  
102. Shoji T, Nishizawa Y: Plasma lipoprotein abnormalities in hemodialysis 
patients – clinical implications and therapeutic guidelines. Ther Apher Dial 
2006; 10: 305–315. 
103. Brown WV: Expert commentary: the safety of fibrates in lipid-lowering 
therapy. Am J Cardiol 2007; 99: 19C–21C. 
104. Davidson MH, Armani A, McKenney JM, Jacobson TA: Safety  
considerations with fibrate therapy. Am J Cardiol 2007; 99: 3C– 18C. 
105. Seliger SL, Weiss NS, Gillen DL, Kestenbaum B, Ball A, Sherrard DJ, 
Stehman- Breen CO: HMG-CoA reductase inhibitors are associated with 
reduced mortality in ESRD patients. Kidney Int 2002; 61: 297– 304. 
106. Tonelli M, Collins D, Robins S, Bloomfield H, Curhan GC: Gemfibrozil 
for secondary prevention of cardiovascular events in mild to moderate 
chronic renal insufficiency. Kidney Int 2004; 66: 1123–1130. 
107. Modified from Romhilt DW, Boveke,Norris et al. A Critical appraisal of 
the electrocardiographic criteria for the diagnosis of left ventricular   
hypertrophy. Circulation 1969; 40;185  
108. Vaziri ND, Moradi H: Mechanisms of dyslipidemia of chronic renal 
failure. Hemodial Int 2006; 10: 1–7. 
  
109. Liu Y, Coresh J, Eustace JA, et al. Association between cholesterol level 
and mortality in dialysis patients: role of inflammation and malnutrition. 
JAMA 2004;291:451. 
110. Fredrickson DS, Levy RI, Lees RS. Fat transport in lipoproteinsâ€“an 
integrated approach to mechanisms and disorders. N Engl J Med 
1967;276:34. 
111. Bagdade JD, Yee E, Wilson D, and Shafrir E. Hyperlipidemia in renal 
failure: studies of plasma lipoproteins, hepatic triglyceride production, and 
tissue lipoprotein lipase in a chronically uremic rat model. J Lab Clin Med 
91: 176–186, 1978. 
112. Chan MK, Varghese Z, and Moorhead JF. Lipid abnormalities in uremia, 
dialysis, and transplantation. Kidney Int 19: 625–637, 1981. 
113. Majumdar A and Wheeler DC. Lipid abnormalities in renal disease.   J R 
Soc Med 93: 178–182, 2000. 
114. Kimura H, Miyazaki R, Imura T, Masunaga S, Suzuki S, Gejyo F, and 
Yoshida H. Hepatic lipase mutation may reduce vascular disease prevalence 
in hemodialysis patients with high CETP levels. Kidney Int 64:1829–1837, 
2003. 
115. Bagdade JD, Shafrir E, and Wilson DE. Mechanism(s) of hyperlipidemia 
in chronic uremia. Trans Am Soc Artif Intern Organs 22:  42– 45, 1976. 
  
116. Cressman MD, Heyka RJ, Paganini EP, O’Neil J, Skibinski CI, Hoff 
HF:Lipoprotein (a) is an independent risk factor for cardiovascular disease 
in hemodialysis patients. Circulation 1992; 86: 475–482. 
117. Shoji T, Nishizawa Y, Kawagishi T, Kawasaki K, Taniwaki H, Tabata T, 
Inoue T, Morii H: Intermediate-density lipoprotein as an independent risk 
factor for aortic atherosclerosis in hemodialysis patients. J Am Soc Nephrol 
1998; 9: 1277–1284. 
118. Kalantar-Zadeh K, Block G, Humphreys MH, et al. Reverse 
epidemiology of cardiovascular risk factors in maintenance dialysis 
patients. Kidney Int 2003;63:793. 
119. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD: Reverse 
epidemiology of cardiovascular risk factors in maintenance dialysis 
patients. Kidney Int 2003; 63: 793– 808. 
120. Liu Y, Coresh J, Eustace JA, et al. Association between cholesterol level 
and mortality in dialysis patients: role of inflammation and  malnutrition. 
JAMA 2004;291:451 
121. National Cholesterol Education Program Adult Treatment Panel 3 
guidelines.JAMA 2001;285;2486-97. 
122. Fielding CJ and Fielding PE. Cellular cholesterol efflux. Biochim 
Biophys Acta 1533: 175–189, 2001. 
  
123. Heart Protection Study Collaborative Group. MRC/BHF Heart 
Protection Study of cholesterol lowering with simvastatin in 20,536 high-
risk individuals: a randomized placebo-controlled trial. Lancet 360: 7–
22,2002. 
 
 
 
 
Proforma 
  
A Study on Dyslipidemia in CKD 
 
 
 
Name of the patient  : 
 
Age / Sex                     : 
 
IP/OP No                     :   
 
Address    : 
 
 
 
                                                    
Height (mts) :                                      Weight (kgs) :                               BMI :  
 
Diagnosis                     :  
 
Chief Complaints        :   
 
 
 
 
Past History of                 
  
1. DM                                                                  : Yes/No                        
2. Coronary heart disease                                    : Yes/No    
3. Hypertension                                                   : Yes/No    
4. Thyroid Disease                                               : Yes/No     
5. Drug intake (Steriods, Anti thyroid drugs,      : Yes/No    
                           Estrogen/OCP, B-blockers) 
6. PD                                                                    : Yes/No    
7. HD                                                                    : Yes/No    
  
Personal History of       
     
       1. Smoking               : 
       2.Alcoholism            :  
General Examination               
 
        PR (per min)   : 
        BP ( mm Hg)   : 
        Xanthomas/Xanthelesma : 
        Arcus senilis    :  
        Fundus changes   :  
 
Systemic Examination    
     
        CVS                                 : 
        RS                                    : 
        Abdomen                         : 
        CNS                                 :  
 
Investigations  
 
Blood sugar(mg/dL)  : 
Urea (mg/dL)  : 
Creatinine (mg/dL) : 
Sodium(mEql/L)  : 
Potassium (mEql/L) : 
Creatinine clearance  :  
                  (ml/min) 
Lipid profile(mg/dL)    
TC                           : 
TGL                         : 
HDL –C                   : 
LDL- C                    : 
Ratio of TC              : 
 to HDL-C        
 
          USG abdomen               : 
 
          ECG                              : 
 
Table 1. Age Distribution in this Study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Sex Distribution in this Study 
 
 
 
Sex 
No of 
Patients Percentage 
Male 32 64 
Female 18 36 
 
 
 
 
 
 
 
 
Age (Yrs) 
No of 
Patients Percentage 
< 28 0 0 
28 - 35 12 24 
36 - 40 17 34 
41 - 45 10 20 
46 - 50 8 16 
51 - 55 3 6 
Age Distribution in this Study 
 
 
 
46 - 50 Yrs
16%
51 - 55 Yrs
6% 28 - 35 Yrs
24%
36 - 40 Yrs
34%
41 - 45 Yrs
20%
 
 
 
 
 
 
 
Sex Distribution in this Study 
 
 
Female
36%
Male
64%
 
 
 
 
Table 3. Classification of Systemic Hypertension JNC-VII 
 
 
 
 
     When systolic and diastolic pressure falls into different categories, the 
higher category should be selected to classify the individuals BP. 
 
     Isolated Systemic Hypertension is defined as systolic BP of greater than 140 
mmHg and a diastolic BP of less than 90 mmHg. 
 
 
Table 4. Systemic Hypertension in the Study 
 
 
BP Classification 
 
Number of 
Patients Percentage 
Stage 1 hypertension 26 52 
Stage 2 hypertension 24 48 
 
 
 
 
 
 
BP Classification 
 
SBP mm Hg 
 
DBP mm Hg 
 
Normal <120 and <80 
Prehypertension 120–139 or 80–89 
Stage 1 hypertension 140–159 or 90–99 
Stage 2 hypertension 160 or 100 
Table 5. Blood Urea – An Analysis in this Study 
 
 
Blood Urea 
(mg/dL) 
No. of 
Patients Percentage 
47-59 12 24 
60-69 7 14 
70-79  8 16 
80-89  2 4 
90-99 3 6 
100-109  1 2 
110-119 4 8 
120-129  2 4 
130-139 2 4 
140-149 2 4 
150-159 5 10 
>160  2 4 
 
 
 
Table 6. Serum Creatinine – An Analysis in this Study 
 
 
Serum 
Creatinine 
(mg/dL) 
No. of 
Patients Percentage 
3-5.9 16 32 
6-8.9 20 40 
9-11.9 14 28 
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Serum Creatinine – An Analysis in this Study 
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Table 7. Statistical Analysis – Study Group 
 
 
 
 
 
 
 
 
 
 
 
Table 8. Statistical Analysis – Control Group 
 
 
 
 TC TGL HDL-C LDL-C Ratio
Mean 178.48 127.78 52.9 100.02 3.5
Mean Deviation 16.66 20.54 8.82 19.55 0.7
Std Deviation 20.34 27.53 10.41 23.92 0.9
Std Error of Mean 2.88 3.89 1.47 3.38 0.1
 
 
 
 
 
 TC TGL HDL-C LDL-C Ratio
Mean 192.24 197.26 34.18 118.61 5.7 
Mean Deviation 14.64 45.51 3.46 14.72 0.8 
Std Deviation 22.55 59.75 4.62 21.27 1.0 
Std Error of Mean 3.19 8.45 0.65 3.01 0.1 
Std Error of 
Difference Between 
Two Mean 4.29 9.30 1.61 4.53 0.2 
 
Table 9. Lipid Abnormality in Study Group 
 
 
Lipid 
Disorder 
Both Male and 
Female in  %  
(No of Patients) 
Among the 32 
Males in  %  
(No of 
Patients) 
Among the 18 
Females in  %  
(No of 
Patients) 
Increased 
TC 26 (13) 28.1(9) 22.2(4) 
Increased 
TGL 78(39) 75 (24) 83.3(15) 
Decreased 
HDL 90 (45) 87.5 (28) 94.4 (17) 
Increased 
LDL 28(14) 25(8) 33.3(6) 
 
 
 
Table 10. Lipid Abnormality in Control Group 
 
 
Lipid Disorder No. of Patients Percentage 
Increased TC 7 14 
Increased 
TGL 3 6 
Decreased 
HDL 3 6 
Increased 
LDL 4 8 
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Table 11.  ECG Changes in CKD Patients 
 
 
 
 
Table 12. Comparative Analysis of Previous Reports with Present Study 
 
Study TC TGL HDL-C LDL-C 
Liu Y, 
Coresh J, 
Eustace JA, 
et al. 
Normal or 
even low 
Increased Decreased Normal 
Vaziri ND 
et al. 
Normal or 
even low 
Increased Decreased Normal or 
slightly 
reduced 
Present 
study 
Increased Increased Decreased Increased 
 
 
Type of 
ECG 
changes  
Both Male and 
Female  in  %  
(No of Patients) 
Among the 32 
Males  in  %  
(No of Patients) 
Among the 18 
Females in  %  
(No of Patients) 
LVH  16 (8) 18.8 (6) 11.1 (2) 
Ischemia 28 (14) 18.8 (6) 44.4 (8) 
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                                            Lipid Profile – Control Group 
 
 
 
S.No TC TGL 
HDL-
C 
LDL-
C Ratio 
26 170 138 66 76 2.6
27 159 92 60 81 2.7
28 142 198 53 49 2.7
29 160 108 58 80 2.8
30 214 148 60 124 3.6
31 154 134 58 69 2.7
32 192 100 58 114 3.3
33 141 126 46 70 3.1
34 182 148 42 110 4.3
35 168 131 49 93 3.4
36 197 98 40 137 4.9
37 160 92 44 98 3.6
38 177 94 53 105 3.3
39 199 140 58 113 3.4
40 178 150 52 96 3.4
41 180 144 59 92 3.1
42 170 72 60 96 2.8
43 195 84 62 116 3.1
44 173 86 64 92 2.7
45 184 142 68 88 2.7
46 200 98 60 120 3.3
47 150 104 64 65 2.3
48 153 142 46 79 3.3
49 154 142 45 81 3.4
50 167 138 41 98 4.1
S.No TC TGL 
HDL-
C 
LDL-
C Ratio 
1 202 212 40 120 5.1
2 192 140 46 118 4.2
3 205 132 41 138 5.0
4 193 128 45 122 4.3
5 191 144 42 120 4.5
6 205 140 38 139 5.4
7 204 140 54 122 3.8
8 178 118 56 98 3.2
9 183 144 59 95 3.1
10 170 132 43 101 4.0
11 199 124 76 98 2.6
12 183 146 39 115 4.7
13 188 132 47 115 4.0
14 230 140 48 154 4.8
15 146 122 50 72 2.9
16 152 134 41 84 3.7
17 171 128 45 100 3.8
18 164 122 53 87 3.1
19 179 140 78 73 2.3
20 159 104 69 69 2.3
21 160 112 70 68 2.3
22 209 114 39 147 5.4
23 194 102 45 129 4.3
24 177 98 48 109 3.7
25 171 192 67 66 2.6
